Purchase by Mark Vignola of 743 shares of Terns Pharmaceuticals

TERN Stock  USD 7.08  0.72  11.32%   
About 51% of Terns Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Terns Pharmaceuticals stock suggests that some investors are interested at this time. Terns Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Terns Pharmaceuticals. Many technical investors use Terns Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Terns Pharmaceuticals Inc officer. General open market or private purchase of non-derivative or derivative security

Read at macroaxis.com
Terns insider trading alert for perchase of common stock by Mark Vignola, Chief Financial Officer, on 4th of December 2023. This event was filed by Terns Pharmaceuticals Inc with SEC on 2023-12-04. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Terns Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Terns Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Terns Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Terns Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Terns Pharmaceuticals Fundamental Analysis

We analyze Terns Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Terns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Terns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Retained Earnings

Retained Earnings Comparative Analysis

Terns Pharmaceuticals is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Terns Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Terns Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Terns Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Terns Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Terns Pharmaceuticals Related Equities

XFORX4 Pharmaceuticals   2.70   
0%
60.0%
INZYInozyme Pharma   2.67   
0%
60.0%
DAWNDay One   1.55   
0%
34.0%
MREOMereo BioPharma   0.28   
0%
6.0%
ABOSAcumen Pharmaceuticals   0.88   
19.0%
0%
AMLXAmylyx Pharmaceuticals   1.68   
37.0%
0%
ELDNEledon Pharmaceuticals   1.68   
37.0%
0%
HOOKHookipa Pharma   2.75   
61.0%
0%
PDSBPDS Biotechnology   4.44   
100.0%
0%
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:
Check out Terns Pharmaceuticals Hype Analysis, Terns Pharmaceuticals Correlation and Terns Pharmaceuticals Performance.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.31)
Revenue Per Share
0.035
Return On Assets
(0.19)
Return On Equity
(0.28)
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.